Neupogen Singleject (Filgrastim)

Filgrastim, the active ingredient in Neupogen Singleject, is a granulocyte colony-stimulating factor presented as a 300 µg/0.5 mL solution for injection (prefilled syringe) for intravenous or subcutaneous use. It treats neutropenia associated with chemotherapy and other hematologic conditions in patients requiring neutrophil support.

GNH USA supplies Neupogen Singleject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neupogen Singleject (filgrastim) is used to stimulate neutrophil production in a range of hematologic disorders. - Neutropenia associated with chemotherapy: restores neutrophil counts to reduce infection risk. - Aplastic anemia: supports bone‑marrow recovery by promoting neutrophil lineage development. - Peripheral blood stem cell mobilization: enhances stem‑cell yield for collection prior to transplantation. - Myelodysplastic syndromes: improves neutrophil numbers in patients with ineffective hematopoiesis. - Severe chronic neutropenia: provides long‑term neutrophil support to lower infection susceptibility.

Filgrastim may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Bone pain: discomfort in the limbs or back, often related to rapid marrow expansion. - Injection site reactions: redness, swelling, or mild tenderness at the injection site. - Headache: transient mild to moderate headache. - Fatigue: general feeling of tiredness. - Fever: low‑grade temperature elevation. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Splenic rupture: sudden abdominal pain and signs of internal bleeding. - Acute respiratory distress syndrome (ARDS): severe breathing difficulty requiring urgent care. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Leukocytosis: excessively high white‑blood‑cell counts. - Capillary leak syndrome: sudden fluid shift leading to edema and low blood pressure. - Severe bone pain: intense, persistent pain requiring medical intervention.

When using Neupogen Singleject, clinicians should observe several safety measures. - Monitor blood counts: check neutrophil levels regularly to assess response. - Assess for splenomegaly: perform abdominal examinations before and during therapy. - Avoid in patients with known hypersensitivity: do not administer if allergic to filgrastim or excipients. - Use caution in sickle‑cell disease: monitor for vaso‑occlusive crises. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Filgrastim may interact with other medications, requiring attention to potential effects.

Major Interactions (Avoid): - Concurrent use of other colony‑stimulating factors: risk of excessive leukocytosis. - Monoclonal antibodies targeting G‑CSF: may antagonize filgrastim activity. - High‑dose systemic corticosteroids: can blunt neutrophil response.

Moderate Interactions (Monitor Closely): - Cytotoxic chemotherapy agents: may mask myelosuppression if filgrastim timing is altered. - Live vaccines: reduced efficacy; consider timing relative to filgrastim administration. - Anticoagulants: increased risk of bleeding at injection sites. - Certain antibiotics: may affect infection‑risk assessment during neutropenia treatment.